Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Jul 03 2023

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 1 page · English

Summary by 6ix AI

Zydus Lifesciences Limited has received an Establishment Inspection Report from the USFDA for its manufacturing facility at Pharmez, Ahmedabad, following an inspection conducted in March. The inspection was classified as Voluntary Action Indicated, and the report confirms that the inspection is now closed. This disclosure is made in accordance with regulatory requirements for transparency to investors and the exchange.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated July 03, 2023, titled "Zydus receives EIR from the USFDA for its SEZ 1 manufacturing facility at Pharmez, Ahmedabad".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases